|

Nivolumab + Relatlimab Clinical Trials

5 actively recruiting trials across 5 locations

▼ -1 trial since May 2026

Also known as: BMS-986213, Opdualag

Pipeline

Phase 1: 2Phase 2: 3

Top Sponsors

  • NYU Langone Health1
  • H. Lee Moffitt Cancer Center and Research Institute1
  • Exelixis1
  • Carlo Contreras1
  • Bristol-Myers Squibb1

Indications

  • Cancer5
  • Melanoma2
  • Liver Disease1
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)1
  • Urothelial Carcinoma (UC)1

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Phoenix, Arizona1 trial

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis Clinical Site #67

Phase 1

Los Angeles, California1 trial

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

The Angeles Clinic at Cedars Sinai

Phase 2

Tampa, Florida1 trial

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Moffitt Cancer Center

Phase 2

Columbus, Ohio1 trial

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.